145 related articles for article (PubMed ID: 38504394)
1. Safety and efficacy of linaclotide in children aged 7-17 years with irritable bowel syndrome with constipation.
Di Lorenzo C; Nurko S; Hyams JS; Rodriguez-Araujo G; Shakhnovich V; Saps M; Simon M
J Pediatr Gastroenterol Nutr; 2024 Mar; 78(3):539-547. PubMed ID: 38504394
[TBL] [Abstract][Full Text] [Related]
2. Linaclotide in irritable bowel syndrome with constipation: A Phase 3 randomized trial in China and other regions.
Yang Y; Fang J; Guo X; Dai N; Shen X; Yang Y; Sun J; Bhandari BR; Reasner DS; Cronin JA; Currie MG; Johnston JM; Zeng P; Montreewasuwat N; Chen GZ; Lim S
J Gastroenterol Hepatol; 2018 May; 33(5):980-989. PubMed ID: 29319191
[TBL] [Abstract][Full Text] [Related]
3. Linaclotide for irritable bowel syndrome with constipation: a 26-week, randomized, double-blind, placebo-controlled trial to evaluate efficacy and safety.
Chey WD; Lembo AJ; Lavins BJ; Shiff SJ; Kurtz CB; Currie MG; MacDougall JE; Jia XD; Shao JZ; Fitch DA; Baird MJ; Schneier HA; Johnston JM
Am J Gastroenterol; 2012 Nov; 107(11):1702-12. PubMed ID: 22986437
[TBL] [Abstract][Full Text] [Related]
4. A 12-week, randomized, controlled trial with a 4-week randomized withdrawal period to evaluate the efficacy and safety of linaclotide in irritable bowel syndrome with constipation.
Rao S; Lembo AJ; Shiff SJ; Lavins BJ; Currie MG; Jia XD; Shi K; MacDougall JE; Shao JZ; Eng P; Fox SM; Schneier HA; Kurtz CB; Johnston JM
Am J Gastroenterol; 2012 Nov; 107(11):1714-24; quiz p.1725. PubMed ID: 22986440
[TBL] [Abstract][Full Text] [Related]
5. Determining an optimal dose of linaclotide for use in Japanese patients with irritable bowel syndrome with constipation: A phase II randomized, double-blind, placebo-controlled study.
Fukudo S; Nakajima A; Fujiyama Y; Kosako M; Nakagawa A; Akiho H; Nakashima Y; Johnston JM; Miwa H
Neurogastroenterol Motil; 2018 May; 30(5):e13275. PubMed ID: 29278278
[TBL] [Abstract][Full Text] [Related]
6. Dose-finding study of linaclotide in Japanese patients with chronic constipation: A phase II randomized, double-blind, and placebo-controlled study.
Fukudo S; Miwa H; Nakajima A; Kinoshita Y; Kosako M; Nakagawa A; Akiho H; Kuroishi K; Johnston JM; Currie M; Ohkusa T
Neurogastroenterol Motil; 2018 Dec; 30(12):e13442. PubMed ID: 30084233
[TBL] [Abstract][Full Text] [Related]
7. Randomized controlled trial of linaclotide in children aged 6-17 years with functional constipation.
Di Lorenzo C; Nurko S; Hyams JS; Rodriguez-Araujo G; Almansa C; Shakhnovich V; Saps M; Simon M
J Pediatr Gastroenterol Nutr; 2024 May; 78(5):1059-1068. PubMed ID: 38533633
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of linaclotide in treating functional constipation in paediatric patients: a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial.
Di Lorenzo C; Khlevner J; Rodriguez-Araujo G; Xie W; Huh SY; Ando M; Hyams JS; Nurko S; Benninga MA; Simon M; Hewson ME; Saps M
Lancet Gastroenterol Hepatol; 2024 Mar; 9(3):238-250. PubMed ID: 38211604
[TBL] [Abstract][Full Text] [Related]
9. A randomized controlled and long-term linaclotide study of irritable bowel syndrome with constipation patients in Japan.
Fukudo S; Miwa H; Nakajima A; Haruma K; Kosako M; Nakagawa A; Akiho H; Yamaguchi Y; Johnston JM; Currie M; Kinoshita Y
Neurogastroenterol Motil; 2018 Dec; 30(12):e13444. PubMed ID: 30136447
[TBL] [Abstract][Full Text] [Related]
10. Effects of linaclotide in patients with irritable bowel syndrome with constipation or chronic constipation: a meta-analysis.
Videlock EJ; Cheng V; Cremonini F
Clin Gastroenterol Hepatol; 2013 Sep; 11(9):1084-1092.e3; quiz e68. PubMed ID: 23644388
[TBL] [Abstract][Full Text] [Related]
11. Safety and tolerability of linaclotide for the treatment of chronic idiopathic constipation and irritable bowel syndrome with constipation: pooled Phase 3 analysis.
Nee JW; Johnston JM; Shea EP; Walls CE; Tripp K; Shiff S; Fox SM; Bochenek W; Weissman D; Currie MG; Lembo AJ
Expert Rev Gastroenterol Hepatol; 2019 Apr; 13(4):397-406. PubMed ID: 30791771
[TBL] [Abstract][Full Text] [Related]
12. Multicentre, non-interventional study of the efficacy and tolerability of linaclotide in the treatment of irritable bowel syndrome with constipation in primary, secondary and tertiary centres: the Alpine study.
Pohl D; Fried M; Lawrance D; Beck E; Hammer HF
BMJ Open; 2019 Dec; 9(12):e025627. PubMed ID: 31892640
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of linaclotide in patients with irritable bowel syndrome with constipation: Chinese sub-cohort analysis of a phase III, randomized, double-blind, placebo-controlled trial.
Peng LH; Fang JY; Dai N; Shen XZ; Yang YL; Sun J; Yang YS
J Dig Dis; 2022 Feb; 23(2):99-110. PubMed ID: 35019221
[TBL] [Abstract][Full Text] [Related]
14. Effect of linaclotide on severe abdominal symptoms in patients with irritable bowel syndrome with constipation.
Rao SS; Quigley EM; Shiff SJ; Lavins BJ; Kurtz CB; MacDougall JE; Currie MG; Johnston JM
Clin Gastroenterol Hepatol; 2014 Apr; 12(4):616-23. PubMed ID: 24075889
[TBL] [Abstract][Full Text] [Related]
15. Low-Dose Linaclotide (72 μg) for Chronic Idiopathic Constipation: A 12-Week, Randomized, Double-Blind, Placebo-Controlled Trial.
Schoenfeld P; Lacy BE; Chey WD; Lembo AJ; Kurtz CB; Reasner DS; Bochenek W; Tripp K; Currie MG; Fox SM; Blakesley RE; OʼDea CR; Omniewski ND; Hall ML
Am J Gastroenterol; 2018 Jan; 113(1):105-114. PubMed ID: 29091082
[TBL] [Abstract][Full Text] [Related]
16. Effect of 5 days linaclotide on transit and bowel function in females with constipation-predominant irritable bowel syndrome.
Andresen V; Camilleri M; Busciglio IA; Grudell A; Burton D; McKinzie S; Foxx-Orenstein A; Kurtz CB; Sharma V; Johnston JM; Currie MG; Zinsmeister AR
Gastroenterology; 2007 Sep; 133(3):761-8. PubMed ID: 17854590
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of linaclotide for patients with chronic constipation.
Lembo AJ; Kurtz CB; Macdougall JE; Lavins BJ; Currie MG; Fitch DA; Jeglinski BI; Johnston JM
Gastroenterology; 2010 Mar; 138(3):886-95.e1. PubMed ID: 20045700
[TBL] [Abstract][Full Text] [Related]
18. Randomized Trial of 2 Delayed-Release Formulations of Linaclotide in Patients With Irritable Bowel Syndrome With Constipation.
Chey WD; Sayuk GS; Bartolini W; Reasner DS; Fox SM; Bochenek W; Boinpally R; Shea E; Tripp K; Borgstein N
Am J Gastroenterol; 2021 Feb; 116(2):354-361. PubMed ID: 33065589
[TBL] [Abstract][Full Text] [Related]
19. Randomised clinical trials: linaclotide phase 3 studies in IBS-C - a prespecified further analysis based on European Medicines Agency-specified endpoints.
Quigley EM; Tack J; Chey WD; Rao SS; Fortea J; Falques M; Diaz C; Shiff SJ; Currie MG; Johnston JM
Aliment Pharmacol Ther; 2013 Jan; 37(1):49-61. PubMed ID: 23116208
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and Tolerability of Guanylate Cyclase-C Agonists for Irritable Bowel Syndrome with Constipation and Chronic Idiopathic Constipation: A Systematic Review and Meta-Analysis.
Shah ED; Kim HM; Schoenfeld P
Am J Gastroenterol; 2018 Mar; 113(3):329-338. PubMed ID: 29380823
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
